Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2015 · 10-Q
Revenue$49.00K$49.00K−12.5% vs Q2 2014 Net Income-$10.18M-$10.18MN/M vs Q2 2014 EPS Diluted-$0.41-$0.41N/M vs Q2 2014 Operating Income-$6,632,207N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,885,405N/M Margins · derivedOperating margin-13535.1%−7746.5 pt vs Q2 2014
Net margin-20775.6%−18852.2 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 10, 2015 · 41 d after period end